thiotepa has been researched along with Acute Myelogenous Leukemia in 44 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 9.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 5.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| "Rapidly fatal acute myelogenous leukemia (AML) occurred in a woman with advanced (Stage III) ovarian carcinoma who was treated with thiotepa for 30 months." | 4.75 | Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy. ( Kapadia, SB; Krause, JR, 1978) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and alemtuzumab (10-20 mg)." | 3.78 | Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. ( Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R, 2012) |
| "Toxicity included mostly infections." | 2.75 | Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. ( Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL, 2010) |
| "Diagnoses were AML (n=18), ALL (n=3), multiple myeloma (n=11), lymphoma (n=16) and CML (n=1)." | 2.73 | A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. ( Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A, 2008) |
| "Thiotepa (TTP) is an alkylating agent that has been used mainly in breast and ovarian cancer with 20-50% response rates." | 2.69 | The role of thiotepa in autologous bone marrow transplantation for acute leukemia. ( Finlander, R; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G, 1998) |
| "For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population." | 1.91 | Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. ( Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z, 2023) |
| "Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far." | 1.72 | Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022) |
| "We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion." | 1.62 | Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. ( Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I, 2021) |
| "Relapsed acute myeloid leukemia presenting as an isolated central nervous system myeloid sarcoma (CNS MS) is very rare and generally entails poor outcomes." | 1.56 | Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. ( Barbour, M; Bujold, KE; Dandekar, S, 2020) |
| "We compared outcomes of de-novo acute myeloid leukemia patients in complete remission receiving NTD-Haplo (n = 186) vs." | 1.48 | Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. ( Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J, 2018) |
| "Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation." | 1.43 | Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro ( Arcese, W; Bacigalupo, A; Beelen, D; Cornelissen, J; de Rosa, G; Eder, S; Kuball, J; Labopin, M; Majolino, I; Mohty, M; Nagler, A; Or, R; Schaap, NP; Veelken, H; Volin, L, 2016) |
| "Clofarabine was administered at a dose of 30 or 40 mg/m(2)/day over 2 hr for five consecutive days in six patients each." | 1.36 | Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. ( Kobos, R; Shukla, N; Steinherz, L; Steinherz, PG, 2010) |
| "Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T cell-depleted allogeneic bone marrow transplants from HLA-identical sibling donors." | 1.30 | T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. ( Black, PM; Bleau, SA; Boulad, F; Carabasi, MH; Castro-Malaspina, H; Childs, BH; Collins, NH; Gillio, AP; Heller, G; Kernan, NA; Mackinnon, S; O'Reilly, RJ; Papadopoulos, EB; Small, TN; Szabolcs, P; Taylor, J; Yahalom, J; Young, JW, 1998) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (25.00) | 18.7374 |
| 1990's | 3 (6.82) | 18.2507 |
| 2000's | 3 (6.82) | 29.6817 |
| 2010's | 16 (36.36) | 24.3611 |
| 2020's | 11 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramaswamy, K | 1 |
| Steinherz, PG | 3 |
| Agrawal, AK | 1 |
| Forlenza, CJ | 1 |
| Mauguen, A | 1 |
| Roshal, M | 1 |
| Trippett, T | 1 |
| Kernan, NA | 3 |
| Sulis, ML | 1 |
| Shukla, N | 3 |
| Swoboda, R | 1 |
| Labopin, M | 9 |
| Giebel, S | 1 |
| Angelucci, E | 5 |
| Arat, M | 1 |
| Aljurf, M | 2 |
| Sica, S | 2 |
| Pavlu, J | 1 |
| Socié, G | 3 |
| Bernasconi, P | 1 |
| Rigacci, L | 1 |
| Tischer, J | 2 |
| Risitano, A | 1 |
| Rovira, M | 1 |
| Saccardi, R | 2 |
| Pioltelli, P | 2 |
| Van Gorkom, G | 1 |
| Vitek, A | 1 |
| Savani, BN | 3 |
| Spyridonidis, A | 3 |
| Peric, Z | 1 |
| Nagler, A | 9 |
| Mohty, M | 9 |
| Finke, J | 5 |
| Schmoor, C | 2 |
| Stelljes, M | 1 |
| Burchert, A | 1 |
| Dreger, P | 1 |
| Hegenbart, U | 1 |
| Wagner-Drouet, EM | 1 |
| Bornhäuser, M | 1 |
| Sohlbach, K | 1 |
| Schub, N | 1 |
| Reicherts, C | 1 |
| Kobbe, G | 1 |
| Glass, B | 1 |
| Bertz, H | 4 |
| Grishina, O | 1 |
| Banet, A | 1 |
| Bazarbachi, A | 3 |
| Stocker, N | 1 |
| Duléry, R | 1 |
| Malard, F | 1 |
| Van de Wyngaert, Z | 1 |
| Genthon, A | 1 |
| Memoli, M | 1 |
| Legrand, O | 1 |
| Bonnin, A | 1 |
| Ledraa, T | 1 |
| Belhocine, R | 1 |
| Sestili, S | 1 |
| El-Cheikh, J | 2 |
| Brissot, E | 1 |
| Luo, C | 1 |
| Wu, G | 1 |
| Huang, X | 1 |
| Ding, Y | 1 |
| Huang, Y | 1 |
| Song, Q | 1 |
| Hou, Y | 1 |
| Chen, J | 2 |
| Li, X | 1 |
| Xu, S | 1 |
| Halahleh, KA | 3 |
| Ma'koseh, M | 3 |
| Sultan, I | 3 |
| Rimawi, DH | 3 |
| Muradi, I | 3 |
| Gale, RP | 3 |
| Cassanello, G | 1 |
| Serpenti, F | 1 |
| Bagnoli, F | 1 |
| Saporiti, G | 1 |
| Goldaniga, M | 1 |
| Cavallaro, F | 1 |
| Barbullushi, K | 1 |
| Bellani, V | 1 |
| Galassi, G | 1 |
| Onida, F | 1 |
| Sora, F | 1 |
| Grazia, CD | 1 |
| Chiusolo, P | 1 |
| Raiola, AM | 1 |
| Bregante, S | 1 |
| Mordini, N | 1 |
| Olivieri, A | 2 |
| Iori, AP | 2 |
| Patriarca, F | 1 |
| Grisariu, S | 2 |
| Terruzzi, E | 1 |
| Rambaldi, A | 4 |
| Bruno, B | 3 |
| Bacigalupo, A | 2 |
| Al-Chami, F | 1 |
| Santarone, S | 4 |
| Bonifazi, F | 2 |
| Carella, AM | 1 |
| Castagna, L | 2 |
| La Nasa, G | 1 |
| Savani, B | 2 |
| Blaise, D | 3 |
| Forcade, E | 1 |
| Berceanu, A | 1 |
| Bulabois, CE | 1 |
| Kröger, N | 2 |
| Ceballos, P | 1 |
| Mielke, S | 1 |
| El Cheikh, J | 1 |
| Yakoub-Agha, I | 2 |
| Saraceni, F | 2 |
| Beohou, E | 1 |
| Arcese, W | 3 |
| Stepensky, P | 1 |
| Passweg, J | 1 |
| Lanza, F | 1 |
| Giannotti, F | 1 |
| Shouval, R | 1 |
| Sanz, J | 1 |
| Sierra, J | 1 |
| Santasusana, JR | 1 |
| Benedetto, B | 1 |
| Carella, MA | 1 |
| Rocha, V | 1 |
| Baron, F | 1 |
| Ruggeri, A | 1 |
| Sheth, V | 1 |
| Nachmias, B | 1 |
| Avni, B | 1 |
| Or, R | 3 |
| Shapira, M | 1 |
| Bujold, KE | 1 |
| Dandekar, S | 1 |
| Barbour, M | 1 |
| Brecht, A | 1 |
| Eder, M | 1 |
| Labussière-Wallet, H | 1 |
| Einsele, H | 1 |
| Beelen, D | 2 |
| Bunjes, D | 2 |
| Niederwieser, D | 1 |
| Bochtler, T | 1 |
| Pagliardini, T | 1 |
| Harbi, S | 1 |
| Porta, MD | 1 |
| Rey, J | 1 |
| Fürst, S | 1 |
| Bramanti, S | 1 |
| Saillard, C | 1 |
| Legrand, F | 1 |
| Maisano, V | 1 |
| Faucher, C | 1 |
| Granata, A | 1 |
| Hospital, MA | 1 |
| Lining, W | 1 |
| Weiller, PJ | 1 |
| Calmels, B | 1 |
| Charbonnier, A | 1 |
| Lemarie, C | 1 |
| Chabannon, C | 1 |
| Vey, N | 1 |
| Mokart, D | 1 |
| Devillier, R | 1 |
| Bayraktar, UD | 1 |
| de Lima, M | 2 |
| Saliba, RM | 1 |
| Maloy, M | 1 |
| Castro-Malaspina, HR | 1 |
| Rondon, G | 2 |
| Chiattone, A | 1 |
| Jakubowski, AA | 1 |
| Boulad, F | 2 |
| O'Reilly, RJ | 2 |
| Champlin, RE | 2 |
| Giralt, S | 3 |
| Andersson, BS | 2 |
| Papadopoulos, EB | 2 |
| Kobos, R | 2 |
| Renaud, T | 1 |
| Steinherz, LJ | 1 |
| Srour, SA | 1 |
| Borders, EB | 1 |
| Cherry, MA | 1 |
| Holter, J | 1 |
| Herman, T | 1 |
| Selby, GB | 1 |
| Eder, S | 2 |
| Majolino, I | 1 |
| de Rosa, G | 1 |
| Volin, L | 1 |
| Veelken, H | 1 |
| Schaap, NP | 1 |
| Kuball, J | 1 |
| Cornelissen, J | 1 |
| Tachibana, T | 1 |
| Tanaka, M | 1 |
| Hagihara, M | 1 |
| Kawasaki, R | 1 |
| Yamazaki, E | 1 |
| Koharazawa, H | 1 |
| Taguchi, J | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Sakai, R | 1 |
| Fujita, H | 1 |
| Fujisawa, S | 1 |
| Maruta, A | 1 |
| Ishigatsubo, Y | 1 |
| Kanamori, H | 1 |
| Kanz, L | 1 |
| Messina, G | 1 |
| Ciurea, SO | 1 |
| Saliba, R | 1 |
| Pesoa, S | 1 |
| Cano, P | 1 |
| Fernandez-Vina, M | 1 |
| Qureshi, S | 1 |
| Worth, LL | 1 |
| McMannis, J | 1 |
| Kebriaei, P | 1 |
| Jones, RB | 1 |
| Korbling, M | 1 |
| Qazilbash, M | 1 |
| Shpall, EJ | 1 |
| Gajewski, J | 2 |
| Steinherz, L | 1 |
| Cluzeau, T | 1 |
| De Matteis, M | 1 |
| Mounier, N | 1 |
| Mannone, L | 1 |
| Gratecos, N | 1 |
| Ticchioni, M | 1 |
| Thyss, A | 1 |
| Raynaud, S | 1 |
| Cassuto, JP | 1 |
| Sirvent, A | 1 |
| Christopoulos, P | 2 |
| Ihorst, G | 1 |
| Marks, R | 2 |
| Wäsch, R | 2 |
| Waterhouse, M | 1 |
| Grüllich, C | 1 |
| Müller, CI | 1 |
| Shimizu, T | 1 |
| Seki, S | 1 |
| Suyama, Y | 1 |
| Fujii, H | 1 |
| Carabasi, MH | 1 |
| Castro-Malaspina, H | 1 |
| Childs, BH | 1 |
| Mackinnon, S | 1 |
| Gillio, AP | 1 |
| Small, TN | 1 |
| Szabolcs, P | 1 |
| Taylor, J | 1 |
| Yahalom, J | 1 |
| Collins, NH | 1 |
| Bleau, SA | 1 |
| Black, PM | 1 |
| Heller, G | 1 |
| Young, JW | 1 |
| Finlander, R | 1 |
| Naparstek, E | 1 |
| Varadi, G | 1 |
| Slavin, S | 1 |
| Worth, L | 1 |
| Tran, H | 1 |
| Petropoulos, D | 1 |
| Culbert, S | 1 |
| Mullen, C | 1 |
| Roberts, W | 1 |
| Przepiorka, D | 2 |
| Chan, K | 1 |
| Bieri, S | 1 |
| Helg, C | 1 |
| Chapuis, B | 1 |
| Miralbell, R | 1 |
| Bibawi, S | 1 |
| Abi-Said, D | 1 |
| Fayad, L | 1 |
| Anderlini, P | 1 |
| Ueno, NT | 1 |
| Mehra, R | 1 |
| Khouri, I | 1 |
| Donato, M | 1 |
| Claxton, D | 1 |
| Braunschweig, I | 1 |
| van Besien, K | 1 |
| Andreeff, M | 1 |
| Estey, EH | 1 |
| Champlin, R | 1 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Young, RC | 1 |
| Kapadia, SB | 1 |
| Krause, JR | 1 |
| Nakanuma, Y | 1 |
| Ohta, G | 1 |
| Saiki, S | 1 |
| Ohta, M | 1 |
| Hisazumi, H | 1 |
| Smit, CG | 1 |
| Meyler, L | 1 |
| Allan, WS | 1 |
| Greenspan, EM | 1 |
| Tung, BG | 1 |
| Ruffner, BW | 1 |
| Kaslow, RA | 1 |
| Wisch, N | 1 |
| Glass, JL | 1 |
| Perlman, M | 1 |
| Walker, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thiotepa and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2023 |
Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy.
Topics: Adult; Aged; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Multiple Primary; Ova | 1978 |
10 trials available for thiotepa and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Rec | 2022 |
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell | 2020 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; | 2019 |
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle | 2014 |
Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Humans; L | 2017 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2010 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2008 |
The role of thiotepa in autologous bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 1999 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bon | 2001 |
32 other studies available for thiotepa and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Clofarabine; Humans; Leukemia | 2022 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transpla | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2021 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2018 |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acut | 2018 |
Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
Topics: Adolescent; Adult; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2019 |
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; | 2020 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic | 2019 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 2013 |
Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dru | 2015 |
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematopoiet | 2016 |
Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cy | 2015 |
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle | 2010 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2011 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyc | 2012 |
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Mal | 2013 |
[Two cases of post-therapeutic acute leukemia].
Topics: Adult; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Squamous Cell; Cobalt R | 1982 |
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Bone Marrow Transplantati | 1998 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2001 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-1977.
Topics: Aged; Carcinoma, Transitional Cell; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acut | 1977 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
[An autopsy case of atypical leukemia occurring during thio-Tepa administration].
Topics: Aged; Humans; Leukemia, Myeloid, Acute; Male; Thiotepa | 1976 |
Acute myeloid leukaemia after treatment with cytostatic agents.
Topics: Adult; Alkylating Agents; Cyclophosphamide; Cystadenoma; Female; Humans; Leukemia, Myeloid, Acute; N | 1970 |
Acute myeloid leukaemia after treatment with cytostatic agents.
Topics: Aged; Female; Humans; Leukemia, Myeloid, Acute; Ovarian Neoplasms; Thiotepa | 1970 |
Acute myeloblastic leukemia after cure of ovarian cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Carcinoma; Endometriosis; Female; Humans; Injections, I | 1974 |
Letter: Androgen role in erythroleukemia after treatment with alkylating agents.
Topics: Adult; Alkylating Agents; Androgens; Carcinoma, Intraductal, Noninfiltrating; Chlorambucil; Cytarabi | 1974 |
Acute leukemia following cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Ovarian | 1972 |
Acute leukemia following cytotoxic chemotherapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute; Thiotepa | 1973 |